NCT02379416 2026-04-01
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
8 trialsNCT04449549 2026-03-27
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07138378 2025-08-22
XS003-11
Xspray Pharma AB
Phase 1 Completed
NCT01863745 2024-08-19
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Phase 2 Completed
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01289028 2017-01-02
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
Novartis
Phase 3 Completed
NCT00441155 2013-05-13
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Novartis
Phase 1 Completed